###begin article-title 0
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 56 61 <span type="species:ncbi:9606">women</span>
Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 144 149 144 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 93 98 <span type="species:ncbi:9606">women</span>
###xml 159 167 <span type="species:ncbi:9606">patients</span>
Breast cancer is the most common female malignancy and a major cause of death in middle-aged women. So far, germline mutations in the BRCA1 and BRCA2 genes in patients with early-onset breast and/or ovarian cancer have not been identified within the Iranian population.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 240 245 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 250 255 250 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 275 280 275 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 294 299 294 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 352 357 352 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 387 392 387 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 141 146 <span type="species:ncbi:9606">women</span>
With the collaboration of two main centres for cancer in Iran, we obtained clinical information, family history and peripheral blood from 83 women under the age of 45 with early-onset breast cancer for scanning of germline mutations in the BRCA1 and BRCA2 genes. We analysed BRCA1 exons 11 and BRCA2 exons 10 and 11 by the protein truncation test, and BRCA1 exons 2, 3, 5, 13 and 20 and BRCA2 exons 9, 17, 18 and 23 with the single-strand conformation polymorphism assay on genomic DNA amplified by polymerase chain reaction.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
Ten sequence variants were identified: five frameshifts (putative mutations - four novel); three missense changes of unknown significance and two polymorphisms, one seen commonly in both Iranian and British populations.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 193 197 193 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA</italic>
Identification of these novel mutations suggests that any given population should develop a mutation database for its programme of breast cancer screening. The pattern of mutations seen in the BRCA genes seems not to differ from other populations studied. Early-onset breast cancer (less than 45 years) and a limited family history is sufficient to justify mutation screening with a detection rate of over 25% in this group, whereas sporadic early-onset breast cancer (detection rate less than 5%) is unlikely to be cost-effective.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 85 86 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 339 340 339 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 527 528 527 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 686 687 686 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 688 689 688 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 54 59 <span type="species:ncbi:9606">women</span>
###xml 302 307 <span type="species:ncbi:9606">women</span>
###xml 626 631 <span type="species:ncbi:9606">women</span>
Worldwide, breast cancer is the most common cancer in women, excluding skin cancers [1], with a lifetime risk of 10% in the general population [2]. In spite of earlier detection and better treatment, largely due to recent technological advances, it is still the second leading cause of cancer death in women, exceeded only by lung cancer [3]. The three commonest cancers, excluding skin cancer, in the Iranian population (females, all ages), are cancers of the oesophagus, breast and cervix, in diminishing order of incidence [4]. A preliminary study showed no significant differences in age-specific incidences among Iranian women with breast cancer, in comparison with other studies [5,6].
###end p 10
###begin p 11
###xml 184 185 184 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 628 629 628 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 330 335 <span type="species:ncbi:9606">women</span>
###xml 356 361 <span type="species:ncbi:9606">women</span>
Hereditary breast cancer is suspected in an individual who has a family history of breast cancer, or breast and ovarian cancer, that is consistent with autosomal dominant inheritance [7]. Many efforts are now under way to reduce the high incidence and mortality associated with breast and ovarian cancer by the early detection of women at high risk. These women, once identified, can be targeted for more aggressive prevention programs. Breast cancer is not a systemic disease at its inception but is progressive; screening can arrest its development and the treatment of advanced breast cancer is often futile and disfiguring [8].
###end p 11
###begin p 12
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 116 117 116 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 125 131 125 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 149 154 149 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 191 197 191 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 225 230 225 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 237 242 237 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 247 252 247 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 328 332 328 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA</italic>
###xml 401 406 401 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 411 416 411 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 521 523 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 524 526 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 727 732 727 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 746 748 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 749 751 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 785 790 785 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 795 800 795 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 385 390 <span type="species:ncbi:9606">Women</span>
###xml 563 568 <span type="species:ncbi:9606">women</span>
###xml 643 648 <span type="species:ncbi:9606">women</span>
###xml 979 984 <span type="species:ncbi:9606">women</span>
In 1990, the first breast cancer susceptibility gene, BRCA1, was localised by linkage analysis to chromosome 17q21 [9]. Miki et al.[10] isolated the BRCA1 gene in 1994. Subsequently, Wooster et al.[11] identified a new gene, BRCA2. Both BRCA1 and BRCA2 are large genes, consisting of 24 and 27 exons, respectively. Mutations in BRCA genes are distributed throughout the coding region. Women who carry BRCA1 and BRCA2 mutations have a significantly increased chance of developing breast cancer before the age of 50 years [12-14]. Some studies indicate that 13% of women who are diagnosed with breast cancer under the age of 30 years, and 7% of women who are diagnosed with breast cancer under the age of 35 years, have germline BRCA1 alterations [12,15]. No molecular genetics study of BRCA1 and BRCA2 germline mutations has been reported in the Iranian population and there are few individuals with strong family histories that have as yet been identified. We therefore selected women who were most likely to harbour germline mutations in these genes.
###end p 12
###begin title 13
Mutational spectrum
###end title 13
###begin p 14
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 175 180 175 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 196 201 196 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 307 312 307 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 467 468 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 474 479 474 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
At present, over 878 distinct mutations, polymorphisms and variants throughout the BRCA1 gene have been discovered [16]. Over 900 distinct alterations have been identified in BRCA2[16] and, as in BRCA1, they are not limited to a particular region of the gene. Most mutations in both genes are private [16]. BRCA1 is considered to be responsible for about one-half of all cases of early-onset breast cancer and for the majority of familial breast and ovarian cancers [9,17]. BRCA1 somatic mutations have never been reported in sporadic breast cancer [18] although they have occasionally been found in sporadic ovarian cancers [19,20].
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
Design
###end title 16
###begin p 17
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 134 139 <span type="species:ncbi:9606">women</span>
We performed the present study to obtain initial experience in identifying germline mutations in the BRCA1 and BRCA2 genes in Iranian women diagnosed with early-onset breast cancer.
###end p 17
###begin p 18
###xml 310 315 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 320 325 320 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
With the cooperation of two main centres for cancer research and treatment in Tehran, Iran, namely the Iranian Centre for Breast Cancer and the Cancer Institute at Tehran University of Medical Sciences, 83 samples derived from 82 unrelated Iranian families were selected for screening of germline mutations in BRCA1 and BRCA2.
###end p 18
###begin p 19
###xml 54 59 <span type="species:ncbi:9606">women</span>
###xml 150 158 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
During 3 years since 1997, the medical records of 152 women diagnosed with breast cancer at the Iranian Centre for Breast Cancer were reviewed and 39 patients were selected for screening. In the 12 months after December 1999, a consecutive series of 44 patients from the Cancer Institute who were diagnosed with breast cancer were chosen for screening. All selected patients from these two centres were under the age of 45 years.
###end p 19
###begin p 20
###xml 13 18 <span type="species:ncbi:9606">women</span>
All selected women were informed that their DNA samples would be analysed for known mutations in genes associated with susceptibility to breast cancer; they were offered the opportunity to receive the results and were asked to sign a second consent form if they chose to learn the results.
###end p 20
###begin title 21
DNA isolation and mutation analysis
###end title 21
###begin p 22
Using a Promega DNA purification kit (catalogue no. LA1620) and in accordance with the manufacturer's protocols, genomic DNA was extracted from peripheral blood lymphocytes at the Pasteur Institute in Tehran, Iran.
###end p 22
###begin p 23
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 102 107 102 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 137 142 137 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
We analysed BRCA1 exon 11 and BRCA2 exons 10 and 11 by the protein truncation test (PTT) [21-23], and BRCA1 exons 2, 3, 5, 13 and 20 and BRCA2 exons 9, 17, 18 and 23 by the single-strand conformation polymorphism (SSCP) assay [24] and heteroduplex analysis [25] by amplification from genomic DNA with the polymerase chain reaction (PCR).
###end p 23
###begin p 24
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 550 555 550 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 560 565 560 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 686 691 686 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 696 701 696 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 881 883 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 884 886 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
Although mutations are scattered throughout both BRCA1 and BRCA2, some coding regions were particularly chosen for several reasons: first, it has been shown that they have a significant role in protein function (exons 2-5, Ring finger domain [26]; exon 11 and exon 20, BRCT domain) [27]; second, exons 10 and 11 cover a large segment of the gene; third, many putative mutations have been reported in these regions; and fourth, the coding regions listed above have been shown in other significant studies [28-32] to be most likely to harbour germline BRCA1 and BRCA2 mutations. A comparison of data from other studies suggests that, with this strategy, about 14% and 22% of mutations in BRCA1 and BRCA2, respectively, would be missed. However, there are no data to indicate the presence of population-specific mutations in Iran; these data must therefore be considered preliminary [28-32].
###end p 24
###begin title 25
The PTT method
###end title 25
###begin p 26
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
Most mutations reported in BRCA1 and BRCA2 cause premature termination of translation, which is readily detectable by PTT; PTT is a very sensitive and efficient tool for mutation detection [28].
###end p 26
###begin p 27
###xml 143 148 143 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 172 177 172 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 270 275 270 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 288 293 288 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
Modified primers containing a T7 promoter and a perfect Kozak consensus sequence were used to generate PCR products of the whole of exon 11 of BRCA1 and exons 10 and 11 of BRCA2 that were suitable for PTT. Each primer pair amplified 3446 base pairs (bp) and 4959 bp for BRCA1 exon 11 and BRCA2 exon 11, respectively. Regions (the 5' and 3' ends) of exon 11 in both genes were screened separately to identify any potential decrease in the sensivity of PTT resulting from the use of such large fragments.
###end p 27
###begin title 28
PCR programme
###end title 28
###begin p 29
###xml 195 196 191 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 230 231 220 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 232 233 222 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 235 236 225 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 250 251 240 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 292 293 281 282 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 327 328 310 311 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 329 330 312 313 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 332 333 315 316 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 348 349 331 332 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 369 372 351 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 975 978 923 924 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 1219 1221 1165 1167 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 1254 1256 1200 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1268 1269 1214 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
PCRs were performed with genomic DNA containing 50 ng of genomic DNA, 1 mul of each primer at 5 pmol/mul, 2 mul of a mixture of dNTPs (each at 2.5 mM), 2.5 mul of 5 x PCR buffer A [300 mM Tris-SO4 (pH 9.1 at 25degreesC), 90 mM (NH4)2SO4 and 5 mM MgSO4] and 2.5 mul of buffer B [300 mM Tris-SO4 (pH 9.1 at 25degreesC), 90 mM (NH4)2SO4 and 10 mM MgSO4], 1 mul of Elongase(R) Enzyme Mix (Invitrogen, Paisley, UK) in accordance with manufacturer's recommendations, and distilled water was added to a final volume of 25 mul. For amplification, each sample was denatured at 94degreesC for 1 min and subjected to 31 cycles of PCR (94degreesC for 25 s, 56degreesC for 1 min, and extension at 68degreesC for 4 min on an Applied Biosystems DNA thermal cycler, Applera Europe BV, Cheshire, UK); this was followed by incubation at 68degreesC for 10 min. The PCR products were checked on a 0.7% agarose gel and a 1 mul sample was used for a coupled transcription-translation reaction (TNT(R) T7 Quick for PCR DNA kit from Promega, Southampton, UK; catalogue no. L5540), in accordance with the instructions of the manufacturer. Full-length artificial proteins of BRCA1 and BRCA2 exon 11, 126 and 182 kDa, respectively, labelled with 35S, were detected after SDS-PAGE [33] (see Fig. 2) on a 2 x Mini-Protean system (Bio-Rad, Hertfordshire, UK, catalogue no. 165-3301).
###end p 29
###begin title 30
The SSCP assay
###end title 30
###begin p 31
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 98 103 98 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
BRCA1 exons 2, 3, 5, 13 and 20, BRCA2 exons 9, 17, 18 and 23 and the 5' and 3' ends of exon 11 of BRCA1 and BRCA2 were analysed with the SSCP method.
###end p 31
###begin p 32
###xml 250 251 238 239 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 253 254 241 242 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 301 304 289 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 746 747 703 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 747 748 704 705 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
PCR was performed on 50 ng of genomic DNA, 1 mul of 5 pmol/mul forward primer, 1 mul of 5 pmol/mul reverse primer, 1.6 mul of a mixture of dNTPs (each at 2.5 mM), 2 mul of 10 x PCR reaction buffer [750 mM Tris-HCl (pH 8.8 at 25degreesC), 200 mM (NH4)2SO4 and 0.1% (v/v) Tween 20], 0.7 unit of Red Hot Taq DNA polymerase, made up to a final volume of 20 mul with distilled water. For amplification, each sample was denatured at 94degreesC for 2 min and subjected to 28-30 cycles of PCR (at 94degreesC for 30 s, at 55-60degreesC for 1 min, and extension at 74degreesC for 1 min on a Perkin-Elmer-Cetus DNA thermal cycler); this was followed by incubation at 72degreesC for 5 min. Annealing temperatures varied according to the melting temperature, Tm, of the primer template.
###end p 32
###begin p 33
SSCP analysis for point mutations was performed under the following conditions: a mixture of 5 mul of a 28-cycle PCR product and 5 mul of loading buffer was denatured for 10 min at 95degreesC, cooled rapidly on ice and separated on a non-denaturing 14% polyacrylamide gel (57:1 acrylamide:bisacrylamide, 3-10% glycerol) in 0.5 x Trisborate-EDTA buffer at 12-16degreesC for 16-20 h at 245 V. Bands were revealed by silver staining.
###end p 33
###begin title 34
Direct sequencing
###end title 34
###begin p 35
All sequence variants were confirmed by using the PCR products of each sequence variant and Big Dye dideoxy-terminator chemistry (Perkin-Elmer) on an ABI 377 DNA sequencer (Applied Biosystems).
###end p 35
###begin title 36
Primer design
###end title 36
###begin p 37
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 168 173 168 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 252 257 252 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 262 267 262 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
For SSCP, splice junctions were included in the analysis in all cases. In addition, four sets of primers were used to screen the 5' and 3' ends of exon 11 of BRCA1 and BRCA2. For PTT, two sets of primers were designed to screen the whole of exon 11 of BRCA1 and BRCA2.
###end p 37
###begin title 38
Results
###end title 38
###begin p 39
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 112 113 112 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
We have identified ten sequence variants in this cohort: five frameshifts, four of which were novel (Figs 1 and 2), three missense changes of unknown significance and two polymorphisms.
###end p 39
###begin p 40
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 170 175 170 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 180 185 180 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
A common polymorphism in BRCA2 [IVS16-14T>C] was identified in both Iranian and British populations. No sequence variant was detected at the 5' and 3' ends of exon 11 in BRCA1 and BRCA2 by SSCP analysis, suggesting that there was no loss of sensitivity in analysing such large fragments by PTT.
###end p 40
###begin p 41
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 13 14 13 14 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
Tables 1 and 2 describe the distribution of BRCA1 and BRCA2 mutations respectively by the type of mutations.
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA</italic>
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 236 237 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 924 926 924 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 767 774 <span type="species:ncbi:9606">patient</span>
This is the first report to describe mutations in the BRCA genes in the Iranian population. The cohort studied all had early-onset (less than 45 years) breast cancer; a subgroup had a family history that was quite limited (Tables 1 and 2) in comparison with most other studies [34-37]. These preliminary data suggest that the spectrum of mutations identified differs little from that seen in other studies, with no recurrent mutation and the mutations spread throughout the genes. Five putative (frameshift) mutations were detected in the group as a whole (6.02% detection rate) in which four mutations were detected among 14 individuals with a family history (28.6% detection rate with 95% binomial confidence interval 0.09-0.58), whereas one mutation was seen in a patient among 69 individuals with early onset breast cancer but without a family history (1.5% detection rate with 95% binomial confidence interval 0-0.09) [38].
###end p 43
###begin p 44
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
In many of the study cohort, we failed to identify a causative mutation, regardless of the presence or absence of a family history and these may simply be sporadic cases. However, it is clear that the known genes cannot explain most of the variation in breast cancer risk in the population. The difficulties of identifying further genes by linkage indicate that the remaining genes might be numerous, with relatively common alleles conferring moderate risks. Only by identifying these genes will the true pattern of risk and the mechanism behind them become clear [39].
###end p 44
###begin title 45
Conclusions
###end title 45
###begin p 46
The detection rate in those with a family history was high, especially when compared with other studies in which the selection criteria for screening required a much stronger family history. This suggests that the screening, albeit incomplete, was well targeted. The low detection rate in those with apparently sporadic early-onset cancer suggests that early-onset cancer alone is insufficient to justify screening in the Iranian population. If these results were confirmed on a large cohort, molecular methods would form a vital part of any screening programme in Iran.
###end p 46
###begin title 47
GenBank accession numbers
###end title 47
###begin p 48
These sequence variants have already been submitted to GenBank: accession numbers AF274503, AF284812, AF288936, AF288937, AF288938, AF309413, AF317283, AF348515, AY008850 and AY008851.
###end p 48
###begin title 49
Abbreviations
###end title 49
###begin p 50
PTT = protein truncation test; SSCP = single-strand conformation polymorphism.
###end p 50
###begin title 51
Acknowledgements
###end title 51
###begin p 52
###xml 13 21 <span type="species:ncbi:9606">patients</span>
We thank the patients and their families who participated in this study, and also Zahra Sedighi, Maryam Ansari and Zahra Moghadam for collecting samples and for their contribution to the study. This study was funded by the Iranian Ministry of Health and Medical Education.
###end p 52
###begin article-title 53
Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage.
###end article-title 53
###begin article-title 54
Breast cancer genes - what are the real risks?
###end article-title 54
###begin article-title 55
Cancer statistics.
###end article-title 55
###begin article-title 56
Cancer Incidence, Mortality and Prevalance Worldwide, Ver 1.0, IARC CancerBase No 5.
###end article-title 56
###begin article-title 57
Cancer registration in Iran.
###end article-title 57
###begin article-title 58
UK National Statistics
###end article-title 58
###begin article-title 59
###xml 15 20 <span type="species:ncbi:9606">human</span>
Inheritance of human breast cancer: evidence for autosomal dominant transmission in high risk families.
###end article-title 59
###begin article-title 60
The natural history of breast carcinoma.
###end article-title 60
###begin article-title 61
Linkage of early-onset familial breast cancer to chromosome 17q21.
###end article-title 61
###begin article-title 62
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA.
###end article-title 62
###begin article-title 63
Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q 12-13.
###end article-title 63
###begin article-title 64
###xml 54 59 <span type="species:ncbi:9606">women</span>
BRCA1 mutations in a population-based sample of young women with breast cancer.
###end article-title 64
###begin article-title 65
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.
###end article-title 65
###begin article-title 66
A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes.
###end article-title 66
###begin article-title 67
###xml 51 56 <span type="species:ncbi:9606">women</span>
Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer.
###end article-title 67
###begin article-title 68
Breast Cancer Information Core (BIC)
###end article-title 68
###begin article-title 69
Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families.
###end article-title 69
###begin article-title 70
BRCA1 mutations in primary breast and ovarian carcinomas.
###end article-title 70
###begin article-title 71
Somatic mutations in the BRCA1 gene in sporadic ovarian tumours.
###end article-title 71
###begin article-title 72
A somatic truncating mutation in BRCA2 in a sporadic breast tumor.
###end article-title 72
###begin article-title 73
Protein truncation test (PTT) for rapid detection of translation-terminating mutations.
###end article-title 73
###begin article-title 74
Rapid detection of translation-terminating mutations at the adenomatous polyposis coli (APC) gene by direct protein truncation test.
###end article-title 74
###begin article-title 75
Rapid detection of BRCA1 mutations by the protein truncation test.
###end article-title 75
###begin article-title 76
Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.
###end article-title 76
###begin article-title 77
Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis.
###end article-title 77
###begin article-title 78
###xml 51 58 51 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Identification of a RING protein that can interact in vivo with the BRCA1 gene product.
###end article-title 78
###begin article-title 79
Structure of an XRCC1 BRCT domain: a new protein-protein interaction module.
###end article-title 79
###begin article-title 80
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymptomatic testing and screening.
###end article-title 80
###begin article-title 81
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a gonotype-phenotype correlation.
###end article-title 81
###begin article-title 82
A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families.
###end article-title 82
###begin article-title 83
A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families.
###end article-title 83
###begin article-title 84
BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.
###end article-title 84
###begin article-title 85
###xml 81 82 81 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 66 82 <span type="species:ncbi:10665">bacteriophage T4</span>
Cleavage of structural proteins using the assembly of the head of bacteriophage T4.
###end article-title 85
###begin article-title 86
###xml 73 78 <span type="species:ncbi:9606">women</span>
###xml 106 111 <span type="species:ncbi:9606">women</span>
BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history.
###end article-title 86
###begin article-title 87
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families.
###end article-title 87
###begin article-title 88
The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.
###end article-title 88
###begin article-title 89
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Prevalence of BRCA1 and PRCA2 gene mutation in patients with early-onset breast cancer.
###end article-title 89
###begin article-title 90
Breast cancer - not just whether but when?
###end article-title 90
###begin title 91
Figures and Tables
###end title 91
###begin p 92
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 233 236 233 236 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 308 311 308 311 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 347 352 347 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 431 434 431 434 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c)</bold>
###xml 538 543 538 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 698 703 698 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
Single-strand conformation polymorphism (SSCP) assay for germline mutation in BRCA1 exon 2. Lanes 1 and 4 show normal patterns, and lane 2 and 3 depict the abnormal patterns of single-strand DNA mobility seen on a polyacrylamide gel (b). Frameshift mutation in sample (lane 2) confirmed by direct sequencing (a) that shows a 2 bp (AG) deletion in BRCA1 exon 2 at nucleotides 185-186 that leads to the formation of TGA at codon 39. (c) A frameshift mutation (lane 3) identified by direct sequencing, which revealed a 1 bp (T) insertion in BRCA1 exon 2 between nucleotides 181 and 182, leading to the formation of TGA at codon 40. These frameshift mutations are likely to disrupt the function of the BRCA1 proteins.
###end p 92
###begin p 93
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 232 235 232 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 366 371 364 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
SDS-PAGE analysis of the whole of exon 11 of BRCA2, revealing the capacity of the PTT technique to detect mutations within 4959 bp coding sequences in a single reaction with the use of a coupled transcription-translation system, TNT(R) T7 Quick for PCR DNA kit from Promega. Lanes 1 and 2 show the normal pattern of the full-length (181 kDa) protein from exon 11 of BRCA2; lanes 3-5 show three different sizes of truncated protein, which were identified on 6% SDS-PAGE. Arrows show the sizes and positions of the normal and truncated proteins. Lane 4 shows a mutation occurring close to the 3' end of exon 11 and producing a large protein for which the band migrated close to the top of the gel.
###end p 93
###begin p 94
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
Germline mutations in the BRCA1 gene
###end p 94
###begin p 95
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 6 13 <span type="species:ncbi:9606">patient</span>
*This patient also has a frameshift mutation in exon 11 of BRCA2. BC, breast cancer (early-onset ages are also shown); HA, heteroduplex analysis; OV, ovarian cancer; PS, prostate cancer; PTT, protein truncation test; SSCP, single-strand conformation polymorphism assay.
###end p 95
###begin p 96
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
Germline mutations in the BRCA2 gene
###end p 96
###begin p 97
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 56 62 56 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</sup>
###xml 6 13 <span type="species:ncbi:9606">patient</span>
*This patient has also BRCA1-IVS20+48 dup GTATTCCACTCC. daggerThis common polymorphism was detected in both Iranian and British populations. BC, breast cancer (early-onset ages are also shown); DS, direct sequencing; HA, heteroduplex analysis; n.a., not applicable; PTT, protein truncation test; SSCP, single-strand conformation polymorphism assay.
###end p 97

